The financial foundation has eroded significantly, with total assets falling to $5.9 million in 2026Q1 while debt obligations remain at $2.2 million.
| Total Current Assets | 2.9M | 6.35M | 14.23M | 9.21M | 2.63M | 468K | 0 |
| Cash & Short-Term Investments | 1.48M | 4.89M | 13.98M | 9.16M | 2.27M | 407K | 0 |
| Cash Only | 1.48M | 4.89M | 13.98M | 9.16M | 2.27M | 407K | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 300K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.42M | 1.46M | 18K | 16K | 30K | 24K | 0 |
| Total Non-Current Assets | 3.03M | 3.27M | 2.22M | 2.61M | 2.2M | 0 | 0 |
| Property, Plant & Equipment | 2.98M | 3.22M | 2.22M | 2.61M | 2.2M | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 48K | 48K | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 5.94M | 9.62M | 16.45M | 11.82M | 4.82M | 468K | 0 |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | -49.97% | -41.51% | 39.12% | 145.05% | 930.77% | - | - |
| Total Current Liabilities | 1.83M | 1.76M | 12.73M | 9.18M | 7.07M | 1.76M | 0 |
| Accounts Payable | 0 | 0 | 2.7M | 1.44M | 493K | 233K | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 723K | 706K | 9.17M | 0 | 5.45M | 1.3M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.11M | 1.05M | 460K | 7.24M | 803K | 0 | 0 |
| Current Ratio | 1.59x | 3.61x | 1.12x | 1.00x | 0.37x | 0.27x | - |
| Quick Ratio | 1.59x | 3.61x | 1.12x | 1.00x | 0.37x | 0.27x | - |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.51M | 1.7M | 984K | 1.39M | 1.75M | 0 | 0 |
| Long-Term Debt | 1.51M | 1.7M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.08M | 0 | 984K | 1.39M | 1.75M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.34M | 3.46M | 13.71M | 10.57M | 8.82M | 1.76M | 0 |
| Total Debt | 2.23M | 2.41M | 10.55M | 1.75M | 7.52M | 1.3M | 0 |
| Net Debt | 750K | -2.48M | -3.43M | -7.42M | 5.26M | 893K | 0 |
| Debt / Equity | 0.86x | 0.39x | 3.86x | 1.39x | - | - | - |
| Debt / EBITDA | -0.14x | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.05x | - | - | - | - | - | - |
| Interest Coverage | -88.81x | -90.40x | -557.05x | -111.14x | -6.83x | -394.50x | - |
| Total Equity | 2.6M | 6.16M | 2.73M | 1.25M | -4M | -1.29M | 0 |
| Equity Growth % | 176.32% | 125.08% | 118.28% | 131.36% | -209.77% | - | - |
| Book Value per Share | 1.16 | 2.76 | 1.66 | 0.77 | -2.46 | -0.79 | - |
| Total Shareholders' Equity | 2.6M | 6.16M | 2.73M | 1.25M | -4M | -1.29M | 0 |
| Common Stock | 1K | 1K | 0 | 1K | 1K | 0 | 1.17M |
| Retained Earnings | -59.16M | -54.16M | -35.52M | -24.36M | -7.87M | -2.75M | -1.17M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 1.46M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Critical liquidity depletion risk
As reported in recent financial filings, FibroBiologics' total assets have contracted significantly from $16.4 million in 2024Q4 to just $5.9 million in 2026Q1, signaling a rapid depletion of resources that underscores the company's precarious position as it attempts to fund its clinical-stage research pipeline.
The consistent decline in total assets reflects a business model that is consuming capital at a rate faster than it can be replenished through financing or operations. This trajectory suggests that the company is approaching a critical juncture where the current asset base may no longer support the ongoing costs of its clinical trial programs.
Based on the most recent quarterly data, the company's cash position has dwindled to $1.5 million as of 2026Q1, a sharp decline from the $14.0 million reported in 2024Q4, which indicates an extremely limited runway for continued clinical development and general corporate operations.
The current ratio of 1.59 provides a superficial appearance of stability, but the absolute cash balance is insufficient to cover sustained R&D burn rates. Investors should monitor for immediate dilutive financing events, as the current liquidity profile leaves virtually no margin for operational delays or unexpected clinical trial expenses.
According to historical balance sheet data, shareholders' equity has plummeted to $2.6 million in 2026Q1, down from a peak of $2.7 million in 2024Q4, reflecting the cumulative impact of persistent net losses and the ongoing erosion of the company's book value over the last several quarters.
The negative retained earnings balance of $59.2 million highlights the substantial capital destruction inherent in the company's pre-revenue R&D phase. This trend suggests that the equity base is being systematically depleted, increasing the likelihood that future funding will necessitate significant dilution for existing common shareholders.
As indicated by the latest financial statements, the company's reliance on debt, which stands at $2.2 million in 2026Q1, introduces a layer of financial obligation that complicates the firm's already strained liquidity position during this critical phase of clinical development and capital market dependency.
While the debt-to-equity ratio of 0.86 may appear manageable in isolation, the combination of low cash reserves and recurring debt obligations creates a potential liquidity trap. The absence of revenue means that even modest debt servicing requirements could accelerate the depletion of the remaining cash runway.
Quick answers to the most common questions about buying FBLG stock.
As of 2025, FibroBiologics, Inc. Common Stock (FBLG) had total assets of $9.6M including $6.3M in current assets.
FibroBiologics, Inc. Common Stock (FBLG) carries total debt of $2.4M, offset by $4.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
FibroBiologics, Inc. Common Stock (FBLG) has total shareholders' equity (book value) of $6.2M ($2.76 book value per share). Book value represents the net worth of the company belonging to common stock holders.
FibroBiologics, Inc. Common Stock (FBLG) reported a current ratio of 3.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.